Pulmonary Metastasectomy for Melanoma

Area of Science:

• Oncology
• Surgical Oncology
• Pulmonary Medicine

Background:

• Early-stage melanoma offers a high survival rate (94%), but metastatic disease drastically reduces prognosis.
• Metastatic melanoma survival rates have significantly improved, rising from 18% in 2009 to 52% in 2018 due to targeted therapies and immune checkpoint inhibitors.
• The lung is the most frequent site for melanoma metastasis.

Purpose of the Study:

• To review the evolving criteria for pulmonary metastasectomy in melanoma.
• To highlight the role of thoracic surgeons in the multidisciplinary management of metastatic melanoma.
• To emphasize the impact of advanced therapies on surgical candidacy.

Main Methods:

• Review of current literature on melanoma metastasis and treatment outcomes.
• Analysis of changes in surgical indications for pulmonary metastasectomy.
• Discussion of the integration of systemic therapies with surgical interventions.

Main Results:

• Significant improvement in 5-year survival for metastatic melanoma patients treated with modern therapies.
• Expanded criteria for pulmonary metastasectomy, including cases with extrapulmonary metastasis if complete resection is feasible.
• Increased importance of thoracic surgeons in patient selection and surgical planning.

Conclusions:

• Advances in targeted therapy and immunotherapy have transformed metastatic melanoma treatment.
• Pulmonary metastasectomy remains a critical intervention, with evolving indications.
• A multidisciplinary approach integrating thoracic surgery and systemic therapies optimizes outcomes for metastatic melanoma.